Ajanta Pharma Ltd
NSE:AJANTPHARM

Watchlist Manager
Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd
NSE:AJANTPHARM
Watchlist
Price: 2 623 INR -0.25% Market Closed
Market Cap: 327.6B INR

Ajanta Pharma Ltd
Investor Relations

In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs.

Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.

Show more
Loading
AJANTPHARM
BSE Sensex 30

Earnings Calls

2025 Q3
Jan 30, 2025
Show Transcript
Previous
Next
Vaibhav Global Reports Strong Growth and Positive Outlook for Future
2025 Q3
Jan 30, 2025

Vaibhav Global achieved record quarterly revenue of INR 977 crores, a 10% increase year-over-year. Significant growth was seen in Germany with a 30.7% rise, while U.S. and U.K. revenues grew by 3.6% and 6.5%, respectively. The company anticipates a 12% revenue growth for FY '25, with early-teen growth projected from FY '26 onwards, leveraging its strong operational efficiencies. Successful integration of Ideal World into profitability signifies improved financial health. The gross margin remained above 60%, bolstered by strategic product offerings in lab-grown diamonds, now contributing 10% of revenue. An interim dividend of INR 1.5 per share reflects commitment to returning value to shareholders.

Show Full Analysis

Management

Mr. Yogesh Mannalal Agrawal M.B.A
MD & Executive Director
No Bio Available
Mr. Rajesh Mannalal Agrawal M.B.A
Joint MD & Director
No Bio Available
Mr. Madhusudan Bhagwandas Agrawal B.Sc
Executive Vice Chairman of the Board
No Bio Available
Mr. Arvind K. Agrawal B Com, F.C.A, L.L.B
Chief Financial Officer
No Bio Available
Mr. Gaurang Chinubhai Shah
Senior VP of Legal, VP of Corporate Affairs, Company Secretary & Compliance Officer
No Bio Available
Mr. H. Satish Agrawal M Pharm
President of Tech & Operations
No Bio Available
Mr. Thampy Jacob
Senior Vice President of HR
No Bio Available
Mr. H. Nandkishore Agrawal
President of International Business
No Bio Available
Mr. Pankaj Barbind
Deputy General Manager of Sustainability
No Bio Available
Mr. Jagdish Dwarkadas Joshi
Executive Vice President
No Bio Available

Contacts

Address
MAHARASHTRA
Mumbai
Ajanta House,, Charkop, Kandivli West,
Contacts